Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Thyroid Carcinoma, Anaplastic × Adalimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Arthritis, Rheumatoid 10 Spondylitis, Ankylosing 4 Psoriasis 3 Crohn Disease 3 Colitis, Ulcerative 2 Uveal Melanoma 1 Thyroid Carcinoma, Anaplastic 1 Spondylarthritis 1 Sarcoidosis 1 Plaque Psoriasis 1 Osteoarthritis 1 Nephrotic Syndrome 1 Nephrosis, Lipoid 1 Mucopolysaccharidosis VI 1 Mucopolysaccharidosis II 1 Mucopolysaccharidosis I 1 Mucopolysaccharidoses 1 Melanoma 1 Macular dystrophy, corneal type 1 1 Kidney Diseases 1 Joint Diseases 1 Inflammatory Bowel Diseases 1 Inflammation 1 Healthy Adult Male 1 Healthy 1 Glomerulosclerosis, Focal Segmental 1 Dupuytren Contracture 1 Autoimmune Diseases 1 Arthritis 1

Interventions

trametinib 9 dabrafenib 9 Paclitaxel 9 pembrolizumab 4 fosbretabulin 4 lenvatinib 3 Sorafenib 3 Radiotherapy, Intensity-Modulated 3 efatutazone 2 combretastatin 2 cobimetinib 2 atezolizumab 2 aldesleukin 2 Vemurafenib 2 Trastuzumab 2 Radiotherapy 2 Gefitinib 2 Filgrastim 2 Everolimus 2 Doxorubicin 2 Docetaxel 2 Cisplatin 2 Carboplatin 2 zimberelimab 1 vandetanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tremelimumab 1 tislelizumab 1 tipifarnib 1 surufatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02516774 2016-01-26

TAM-RT

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Withdrawn

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡